REG - Hutchmed China Ltd - HUTCHMED to Announce 2023 Final Results

HUTCHMED (China)Announcement

01/02/2024 08:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240201:nRSA6811Ba&default-theme=true

RNS Number : 6811B  Hutchmed (China) Limited  01 February 2024

HUTCHMED to Announce 2023 Final Results

 

Hong Kong, Shanghai & Florham Park, NJ - Thursday, February 1, 2024:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year
ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern
Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong Kong
Time (HKT).

 

Analysts and investors are invited to join a conference call and audio webcast
presentation with Q&A, conducted by HUTCHMED management.

 

The English conference call and audio webcast will take place at 7:30 am EST /
12:30 pm GMT / 8:30 pm HKT on Wednesday, February 28, 2024.  In addition to
the usual English webcast, there will also be a Chinese (Putonghua) webcast at
7:30 pm EST / 12:30 am GMT / 8:30 am HKT on Thursday, February 29, 2024.
Both webcasts will be available live via the company website at
www.hutch-med.com/event/ (https://www.hutch-med.com/event/) . The presentation
will be available for downloading before the conference call begins. Details
of the conference call dial-in will be provided in the financial results
announcement and on the company website.  A replay will also be available on
the website shortly after the event.

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S. For more information, please visit:
www.hutch‑med.com (https://www.hutch-med.com/)
 or follow us on
LinkedIn (https://www.linkedin.com/company/hutchmed/)
.

 

CONTACTS

 

 Investor Enquiries                                                +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 Ben Atwell / Alex Shaw, FTI Consulting                            +44 20 3727 1030 / +44 7771 913 902 (Mobile) /
                                                                   +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
                                                                   (mailto:HUTCHMED@fticonsulting.com)
 Zhou Yi, Brunswick                                                +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                                   (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure Gordon   +44 20 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORKZGGZNMZGDZG